International Models of Melanoma Management (Australia)
This chapter describes the clinical management of melanoma in Australia, the UK and the USA, addressing the challenges faced by the current models. There is a shortage of dermatologists in the UK and, in the USA, the cost of health care limits access. Australia has the highest rate of skin cancer in the world and a geographically dispersed population with little access to specialist health care in rural areas. Every day, general practitioners (GPs) are confronted with skin cancer patients due to a shortage of dermatologists, but lack the skills to manage these patients and must refer them to specialists or the hospital system, where they might await treatment for up to a year. While the latter is an affordable option for those without private health insurance, patients risk dying while waiting for treatment.
In an attempt to innovate the current model, dedicated skin cancer facilities have been established in which GPs subspecialize in skin cancer medicine through standardized qualifications. Patients can gain quicker access to medical care and receive skin cancer screening, diagnosis, and treatment on-site and within a short period of time. Education providers like HealthCert are similarly revolutionizing primary care, upskilling GPs through with university-certified courses in skin cancer medicine and dermatology. These initiatives reduce the burden on hospitals and dermatologists, and reduce patient waiting times and expenses.
This chapter explores the considerations and advantages of developing and expanding Australian skin cancer services, including the benefits of training GPs in dermoscopy, routine screenings of the general population, and advancement of teledermoscopy services in under-resourced locations.
KeywordsMelanoma management Australia GP training Treatment Skin cancer Dermatology Dermoscopy Diagnosis
- 1.Australian Bureau of Statistics. Private health insurance. 2013. http://www.abs.gov.au/ausstats/abs@.nsf/lookup/E334D0A98272E4DCCA257B39000F2DCF?opendocument. Accessed 24 Mar 2017.
- 2.Elmslie P. Business plan for expansion of the national skin cancer centres for the South Australian Government; 2016.Google Scholar
- 3.Staples, MP, Elwood, M, Burton, RC, Williams, JL, Marks, R, Giles, GG 2006, Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985, Med J Aus, 184, 1, pp. 6–10. https://www.mja.com.au/journal/2006/184/1/non-melanoma-skin-cancer-australia-2002-national-survey-and-trends-1985. Accessed 16 May 2017.
- 4.Cancer Council of Australia. Skin cancer. 2017. http://www.cancer.org.au/about-cancer/types-of-cancer/skin-cancer.html. Accessed 16 May 2017.
- 5.Fransen M, Karahalios A, Sharma N, English DR, Giles GG, Sinclair RD. Non-melanoma skin cancer in Australia. Med J Aus. 2012;197(10):565–8. https://www.mja.com.au/journal/2012/197/10/non-melanoma-skin-cancer-australia. Accessed 16 May 2017CrossRefGoogle Scholar
- 6.Public Health England. Routes to diagnosis 2015 update: malignant melanoma. 2016. pp. 3–5. Available from Site-Specific Data Briefings 2006–2013 at http://www.ncin.org.uk/publications/routes_to_diagnosis. Accessed 25 May 2017.
- 7.British Skin Foundation. Skin cancer. n.d. http://www.britishskinfoundation.org.uk/SkinInformation/SkinCancer.aspx. Accessed 25 May 2017.
- 8.Skin Cancer UK. Skin cancer in the UK: the facts, all-party parliamentary group on skin. n.d. http://www.skcin.org/downloads/SkinCancerUKFacts.pdf. Accessed 25 May 2017.
- 10.Cegedim. Market profile of U.S. dermatologists one key market insight report. 2015. http://us.imshealth.com/Marketing/GTMN/Market-Profile-of-Dermatologists.pdf. Accessed 16 May 2017.
- 11.Guy GP, Machlin SR, Ekwueme DU, Yabroff KR. Prevalence and costs of skin cancer treatment in the U.S., 2002–2006 and 2007–2011. Am J Prev Med. 2015;48(2):183–7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603424/. Accessed 16 May 2017CrossRefPubMedGoogle Scholar
- 12.Chen JT, Kempton SJ, Rao VK. The economics of skin cancer: an analysis of medicare payment data. Plast Reconstr Surg Glob Open. 2016;4(9):e868. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054999/. Accessed 25 May 2017CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Skin Cancer Foundation. Skin cancer facts & statistics. 2017. http://www.skincancer.org/skin-cancer-information/skin-cancer-facts#melanoma. Accessed 16 May 2017.
- 14.National Cancer Institute. Melanoma treatment (PDQ®)–health professional version. 2017. https://www.cancer.gov/types/skin/hp/melanoma-treatment-pdq. Accessed 16 May 2017.
- 15.Corona R, Mele A, Amini M, De Rosa G, Coppola G, Piccardi P, Fucci M, Pasquini P, Faraggiana T. Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J Clin Oncol. 1996;14(4):1218–23. http://ascopubs.org/doi/abs/10.1200/JCO.1918.104.22.1688?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed&. Accessed 16 May 2017CrossRefPubMedGoogle Scholar
- 16.American Cancer Society. Treating melanoma skin cancer, 2016. https://www.cancer.org/cancer/melanoma-skin-cancer/treating.html. Accessed 23 May 2017.
- 21.Sheraz A, Halpern SM. Influence of additional dermoscopy images on teledermatology screening of skin lesions. Br J Dermatol. 2011;165:136.Google Scholar
- 23.Halpern SM, Shall L. Establishment of a primary care-based teledermatology service in Kent. Br J Dermatol. 2011;165(Suppl. 1):135–8.Google Scholar
- 24.Cancer Research UK. Skin cancer incidence statistics, December 2015. 2015. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/skin-cancer/incidence#heading-Four. Accessed 17 May 2017.
- 25.National Skin Cancer Centre. Brochure; 2016.Google Scholar